Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Saved in:
| Title: | Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). |
|---|---|
| Authors: | Finn RS; David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA. RFinn@mednet.ucla.edu., Boer K; Onkologia, Szent Margit Korhaz, Budapest, Hungary., Bondarenko I; Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine., Patel R; Comprehensive Blood and Cancer Center, Bakersfield, CA, USA., Pinter T; Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary., Schmidt M; Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany., Shparyk YV; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine., Thummala A; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA., Voitko N; Kyiv City Clinical Oncology Center, Kyiv, Ukraine., Bananis E; Pfizer Inc, New York, NY, USA., McRoy L; Pfizer Inc, New York, NY, USA., Wilner K; Pfizer Inc, San Diego, CA, USA., Huang X; Pfizer Inc, San Diego, CA, USA., Kim S; Pfizer Inc, San Diego, CA, USA., Slamon DJ; David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA., Ettl J; Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technische Universität München, München, Germany. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2020 Sep; Vol. 183 (2), pp. 419-428. Date of Electronic Publication: 2020 Jul 18. |
| Publication Type: | Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 32683565 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Finn+RS%22">Finn RS</searchLink>; David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA. RFinn@mednet.ucla.edu.<br /><searchLink fieldCode="AU" term="%22Boer+K%22">Boer K</searchLink>; Onkologia, Szent Margit Korhaz, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Bondarenko+I%22">Bondarenko I</searchLink>; Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine.<br /><searchLink fieldCode="AU" term="%22Patel+R%22">Patel R</searchLink>; Comprehensive Blood and Cancer Center, Bakersfield, CA, USA.<br /><searchLink fieldCode="AU" term="%22Pinter+T%22">Pinter T</searchLink>; Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary.<br /><searchLink fieldCode="AU" term="%22Schmidt+M%22">Schmidt M</searchLink>; Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Shparyk+YV%22">Shparyk YV</searchLink>; Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.<br /><searchLink fieldCode="AU" term="%22Thummala+A%22">Thummala A</searchLink>; Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.<br /><searchLink fieldCode="AU" term="%22Voitko+N%22">Voitko N</searchLink>; Kyiv City Clinical Oncology Center, Kyiv, Ukraine.<br /><searchLink fieldCode="AU" term="%22Bananis+E%22">Bananis E</searchLink>; Pfizer Inc, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22McRoy+L%22">McRoy L</searchLink>; Pfizer Inc, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Wilner+K%22">Wilner K</searchLink>; Pfizer Inc, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Huang+X%22">Huang X</searchLink>; Pfizer Inc, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kim+S%22">Kim S</searchLink>; Pfizer Inc, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Slamon+DJ%22">Slamon DJ</searchLink>; David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ettl+J%22">Ettl J</searchLink>; Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technische Universität München, München, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2020 Sep; Vol. 183 (2), pp. 419-428. <i>Date of Electronic Publication: </i>2020 Jul 18. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32683565 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10549-020-05755-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 419 Titles: – TitleFull: Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Finn RS – PersonEntity: Name: NameFull: Boer K – PersonEntity: Name: NameFull: Bondarenko I – PersonEntity: Name: NameFull: Patel R – PersonEntity: Name: NameFull: Pinter T – PersonEntity: Name: NameFull: Schmidt M – PersonEntity: Name: NameFull: Shparyk YV – PersonEntity: Name: NameFull: Thummala A – PersonEntity: Name: NameFull: Voitko N – PersonEntity: Name: NameFull: Bananis E – PersonEntity: Name: NameFull: McRoy L – PersonEntity: Name: NameFull: Wilner K – PersonEntity: Name: NameFull: Huang X – PersonEntity: Name: NameFull: Kim S – PersonEntity: Name: NameFull: Slamon DJ – PersonEntity: Name: NameFull: Ettl J IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2020 Sep Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1573-7217 Numbering: – Type: volume Value: 183 – Type: issue Value: 2 Titles: – TitleFull: Breast cancer research and treatment Type: main |
| ResultId | 1 |